133 related articles for article (PubMed ID: 31060800)
21. [A case of lung infection due to Mycobacterium abscessus].
Tagawa A; Ikehara K; Nishiyama H; Tsuburai T; Shinohara T; Kusano N; Baba T; Shoji A; Kaneko T; Suzuki S; Ishigatsubo Y
Nihon Kokyuki Gakkai Zasshi; 2003 Aug; 41(8):546-50. PubMed ID: 14503341
[TBL] [Abstract][Full Text] [Related]
22. Whole-genome sequencing and epidemiological analysis do not provide evidence for cross-transmission of mycobacterium abscessus in a cohort of pediatric cystic fibrosis patients.
Harris KA; Underwood A; Kenna DT; Brooks A; Kavaliunaite E; Kapatai G; Tewolde R; Aurora P; Dixon G
Clin Infect Dis; 2015 Apr; 60(7):1007-16. PubMed ID: 25452595
[TBL] [Abstract][Full Text] [Related]
23. [Mycobacterium abscessus infection complicated with diabetes mellitus].
Takemura Y; Iwasaki Y; Minagawa T; Nakanishi M; Nagata K; Natsuhara A; Harada H; Nakagawa M
Nihon Kokyuki Gakkai Zasshi; 2002 Jan; 40(1):61-5. PubMed ID: 11925921
[TBL] [Abstract][Full Text] [Related]
24. [Treatment of respiratory tract infections with imipenem/cilastatin in critical patients with respiratory insufficiency].
Unertl K; Ruckdeschel G; Forst H; Lenhart FP
Infection; 1986; 14 Suppl 2():S176-80. PubMed ID: 3759253
[TBL] [Abstract][Full Text] [Related]
25. Use of telavancin in adolescent patients with cystic fibrosis and prior intolerance to vancomycin: A case series.
Bernstein AT; Leigh MW; Goralski JL; Esther CR; McKinzie CJ
J Cyst Fibros; 2018 Nov; 17(6):e48-e50. PubMed ID: 30170755
[TBL] [Abstract][Full Text] [Related]
26.
Degiacomi G; Sammartino JC; Chiarelli LR; Riabova O; Makarov V; Pasca MR
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31766758
[TBL] [Abstract][Full Text] [Related]
27. Reversible black tongue: A little known side effect of imipenem/cilastatin and evidence for novel mode of action.
Zhao S; Fan L; Feng J; Ma P
J Clin Pharm Ther; 2020 Apr; 45(2):370-372. PubMed ID: 31621928
[TBL] [Abstract][Full Text] [Related]
28. Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients.
Roux AL; Catherinot E; Soismier N; Heym B; Bellis G; Lemonnier L; Chiron R; Fauroux B; Le Bourgeois M; Munck A; Pin I; Sermet I; Gutierrez C; Véziris N; Jarlier V; Cambau E; Herrmann JL; Guillemot D; Gaillard JL;
J Cyst Fibros; 2015 Jan; 14(1):63-9. PubMed ID: 25085077
[TBL] [Abstract][Full Text] [Related]
29. Lung transplant outcomes in cystic fibrosis patients with pre-operative Mycobacterium abscessus respiratory infections.
Lobo LJ; Chang LC; Esther CR; Gilligan PH; Tulu Z; Noone PG
Clin Transplant; 2013; 27(4):523-9. PubMed ID: 23710571
[TBL] [Abstract][Full Text] [Related]
30.
Le Run E; Arthur M; Mainardi JL
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866869
[TBL] [Abstract][Full Text] [Related]
31. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group.
Eklund AE; Nord CE
J Antimicrob Chemother; 1993 Jan; 31 Suppl A():79-85. PubMed ID: 8383657
[TBL] [Abstract][Full Text] [Related]
32. Measurement of immunoglobulin G against Mycobacterial antigen A60 in patients with cystic fibrosis and lung infection due to Mycobacterium abscessus.
Ferroni A; Sermet-Gaudelus I; Le Bourgeois M; Pierre-Audigier C; Offredo C; Rottman M; Guillemot D; Bernède C; Vincent V; Berche P; Gaillard JL
Clin Infect Dis; 2005 Jan; 40(1):58-66. PubMed ID: 15614693
[TBL] [Abstract][Full Text] [Related]
33. Inhaled corticosteroids for cystic fibrosis.
Balfour-Lynn IM; Welch K
Cochrane Database Syst Rev; 2016 Aug; (8):CD001915. PubMed ID: 27552284
[TBL] [Abstract][Full Text] [Related]
34. Inhaled corticosteroids for cystic fibrosis.
Balfour-Lynn IM; Welch K
Cochrane Database Syst Rev; 2014 Oct; (10):CD001915. PubMed ID: 25300165
[TBL] [Abstract][Full Text] [Related]
35. Risk/benefit in the treatment of children with imipenem-cilastatin for meningitis caused by penicillin-resistant pneumococcus.
Asensi F; Otero MC; Pérez-Tamarit D; Rodríguez-Escribano I; Cabedo JL; Gresa S; Cantón E
J Chemother; 1993 Apr; 5(2):133-4. PubMed ID: 8515296
[TBL] [Abstract][Full Text] [Related]
36. [Nontuberculous mycobacteria in cystic fibrosis].
Le Bourgeois M; Sermet-Gaudelus I; Catherinot E; Gaillard JL
Arch Pediatr; 2005 Aug; 12 Suppl 2():S117-21. PubMed ID: 16129322
[TBL] [Abstract][Full Text] [Related]
37. Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. European Study Group.
Norrby SR; Finch RG; Glauser M
J Antimicrob Chemother; 1993 Jun; 31(6):927-37. PubMed ID: 8360130
[TBL] [Abstract][Full Text] [Related]
38. Imipenem/cilastatin for pediatric infections in hospitalized patients.
Nalin DR; Hart CB; Shih WJ; Aziz MA
Scand J Infect Dis Suppl; 1987; 52():56-64. PubMed ID: 3331043
[TBL] [Abstract][Full Text] [Related]
39. Prevention of transmission of Mycobacterium abscessus among patients with cystic fibrosis.
Gross JE; Martiniano SL; Nick JA
Curr Opin Pulm Med; 2019 Nov; 25(6):646-653. PubMed ID: 31436542
[TBL] [Abstract][Full Text] [Related]
40. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections.
Garau J; Blanquer J; Cobo L; Corcia S; Daguerre M; de Latorre FJ; León C; Del Nogal F; Net A; Rello J
Eur J Clin Microbiol Infect Dis; 1997 Nov; 16(11):789-96. PubMed ID: 9447899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
